Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.050 -0.080 (-2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
3 AI Stocks That Still Trade Under $10 Per Share
With the artificial intelligence (AI) boom ramping up, check out this short list of hot AI stocks under $10. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
From Lantern Pharma Inc.
Via Business Wire
The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023
Machine learning stocks still have a lot of room left to rise despite a short-term pullback in their stock prices. 
Via InvestorPlace
8 Best Artificial Intelligence Stocks Under $10
If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
The 3 Most Undervalued AI Penny Stocks to Buy Now: August 2023
Not only would I take full advantage of the pullbacks in heavyweight AI stocks, I’d also take advantage of the drops in top AI penny stocks. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True
These top three AI penny stocks offer immense upside ahead, potentially becoming future market leaders amid a $15.7 trillion projection. 
Via InvestorPlace
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
7 AI Stocks to Buy Under $5 in August 2023
These AI stocks to buy for under $5 in August have strong potential as the sector grows throughout 2023 and beyond. 
Via InvestorPlace
RedChip Launches 'Small Stocks, Big Money' Podcast
Via ACCESSWIRE
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
3 AI Stocks to Buy Under $10 in August 2023
The bull market in artificial intelligence is just getting started, creating big opportunity for this list of AI stocks under $10. 
Via InvestorPlace
7 AI Penny Stocks that Could Hit $5 Soon
Here are seven AI penny stocks with huge potential as you look to make life-changing money from the advance of artificial intelligence. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
From Lantern Pharma Inc.
Via Business Wire
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
From Lantern Pharma
Via Business Wire
3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023
These AI penny stocks could potentially offer potent long-term value at tremendously attractive prices at this time 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Via Benzinga
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback